← Back to the tool

Lesion grading

The same sheet as the report form, without submission. You grade an event at the slit lamp, the tool computes the CTCAE grade and flags discordance between ophthalmic and oncological grading. Nothing leaves your browser: no name, no address, no data. The private registry stays on this device and exports to a spreadsheet whenever you want.

No patient data is collected here. Do not mention age, dates, initials or any individual history.

What you receive immediately. At the end, the full summary of your contribution is displayed: keep it or print it. Contribution after contribution, you build a structured record of your own practice.
What you receive afterwards. Contributions are aggregated across all participating centres. The quarterly synthesis is sent to registered contributors only — it is not published on the site. You see your own data; you receive everyone's, because you take part.

Molecule concerned

Molecule — select — ARX788 — HER2 · AS269 (auristatine) · non-cleavable linker Belantamab mafodotin — BCMA · MMAF · non-cleavable linker Depatuxizumab mafodotin — EGFR · MMAF · non-cleavable linker Anetumab ravtansine — Mésothéline · DM4 / ravtansine · cleavable disulfide linker Coltuximab ravtansine — CD19 · DM4 / ravtansine · cleavable disulfide linker Mirvetuximab soravtansine — FRα · DM4 / ravtansine · cleavable disulfide linker Praluzatamab ravtansine — CD166 · DM4 / ravtansine · cleavable disulfide linker Tusamitamab ravtansine — CEACAM5 · DM4 / ravtansine · cleavable disulfide linker Brentuximab vedotin — CD30 · MMAE · valine-citrulline cleavable linker Disitamab vedotin — HER2 · MMAE · valine-citrulline cleavable linker Enfortumab vedotin — Nectine-4 · MMAE · valine-citrulline cleavable linker Polatuzumab vedotin — CD79b · MMAE · valine-citrulline cleavable linker Telisotuzumab vedotin — c-Met · MMAE · valine-citrulline cleavable linker Tisotumab vedotin — Facteur tissulaire · MMAE · valine-citrulline cleavable linker Trastuzumab emtansine — HER2 · DM1 / emtansine · non-cleavable thioether linker Datopotamab deruxtecan — TROP2 · Déruxtécan · cleavable linker Sacituzumab govitecan — TROP2 · SN-38 · cleavable linker Trastuzumab deruxtecan — HER2 · Déruxtécan · cleavable linker Trastuzumab duocarmazine — HER2 · Duocarmycine · valine-citrulline cleavable linker Gemtuzumab ozogamicin — CD33 · Calichéamicine · acid-cleavable hydrazone linker Inotuzumab ozogamicin — CD22 · Calichéamicine · acid-cleavable hydrazone linker Loncastuximab tesirine — CD19 · Dimère de PBD · valine-alanine cleavable linker Other molecule — specify below Context of use — select —Routine practice, approved moleculeOngoing clinical trialEarly access or compassionate useMolecule under evaluation

What you observe

Ocular phenotype observed — select —Microcyst-like epithelial keratopathySuperficial punctate keratitis and dry eyeNeurotrophic keratopathyLimbal stem cell deficiencyConjunctivitis or keratoconjunctivitisOther ocular involvement Frequency among your treated patients — select —Never observedRare — under 10% of patientsFrequent — 10 to 50%Very frequent — over 50%Systematic whenever looked for Most frequent time to onset — select —Under one monthOne to three monthsThree to six monthsOver six monthsVariable, no clear pattern Confidence in your estimate — select —Systematic slit-lamp examinationRegular clinical observationOverall impressionIsolated cases only

CTCAE grading

The term is your clinical judgement: the tool does not guess it. The grade is computed from the official CTCAE v5.0 definitions.

Reported event (CTCAE term) — select —ConjunctivitisDry eyeKeratitisOther eye disordersCorneal ulcer Best-corrected visual acuity of the worse eye — select —20/40 or betterWorse than 20/40, up to 20/20020/200 or worse Loss from baseline — select —No loss, or 3 lines or fewerMore than 3 lines Impact — select —Asymptomatic — clinical observations onlySymptomatic, no limitation of activitiesLimiting instrumental activitiesLimiting self-care

What you do

Prophylaxis you use — chaque élément est indépendant.

Preservative-free artificial tears — select —NoYes, throughout treatmentYes, only if symptomatic Topical corticosteroids — select —NoYes, before and during treatmentYes, around infusions onlyYes, only if involvement occurs Vasoconstrictors (apraclonidine, brimonidine…) — select —NoYes, immediately before each infusionYes, throughout treatment Cold packs — select —NoYes, during infusionYes, before and during infusion Contact lens avoidance — select —NoYes, avoidance recommendedYes, strict avoidance Usual management of the event — select —Continue unchangedWithhold until improvementDose reductionWithhold then resume at reduced dosePermanent discontinuationMultidisciplinary decision Reversibility observed — select —Complete resolutionPartial resolutionFunctional sequelaeNot assessable to date

Grade

No data is transmitted. The computation runs on this device.

Compute without sendingAdd to my private register

Would you like to share this case for the collective registry? Switch to the report form →